A. PharmacokineGc studies performed in Balb/c mice for CCT196969 and CCT241161. Plasma levels at Gme point 24 hr (for CCT196969) or 14 hr (for CCT241161) show concentraGon of 1 µM when administered by oral gavage PO=oral administraGon (10 mg/kg/day); IV=intravenous administraGon (2 mg/kg/day). B. Body weights of mice treated with vehicle, CCT196969 and CCT241161 by oral gavage at 30 mg/kg/day for 4 days. Body weight (g) was monitored daily for the first 4 days then twice a week. Bars represent SEM. *(IV= Intravenous administration, PO=Oral administration, Cmax= maximum concentration, Tmax= time of maximum concentration, AUC(0--t)= area under the concentration time curve, F% =oral bioavailability and T½λz= elimination half life). The purity of the final compounds was determined by HPLC and 1 H-NMR as described above and is higher than 95%.
CCT241161 and CCT196969 were synthesised starting from the amine intermediates 1a
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